ABVC BioPharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ABVC BioPharma, Inc. on July 14, 2022, covering events that occurred on July 10, 2022. The Company is a Nevada corporation with its principal executive offices in Fremont, California, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "ABVC".
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is a modification to the Board of Directors:
- Resignation: Mr. Kuang-Tseng Chen resigned from the Board of Directors effective July 10, 2022, for personal reasons. The Company stated there were no disagreements regarding operations, policies, or practices.
- Appointment: Mr. Yu-Min (Francis) Chung was appointed as a director on July 10, 2022, to fill the vacancy left by Mr. Chen.
Management Commentary and Compensation
Mr. Chung brings experience from Maxpro Ventures (Partner, 2018-2022) and TaiAn Technology (Vice President, 2016-2018). He holds a Ph.D. in Pharmacy from the University of Iowa. His compensation is set at $3,500 per month, consistent with other Company directors. The filing confirms no family relationships between Mr. Chung and other directors or officers, and no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify the effective date of Mr. Chen's resignation and Mr. Chung's appointment (July 10, 2022).
- Confirm Mr. Chung's background in biomedical technology and venture capital as disclosed.
- Note that the resignation was explicitly stated as not being due to any disagreement with the Company.
- Review the standard director compensation of $3,500 monthly.